Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Kosei Takagi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2267-2441; OpenAlex author ID A5077174417. Sources: OpenAlex.

Their work

Papers
15 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 7 papers · 2026: 3 papers

Papers 15

  1. Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/cas.70533↗
  2. Impact of Cirrhosis Outcome Risk Estimator Score on Outcomes Following Pancreatectomy for Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.21873/invivo.14364↗
  3. Predictive Nomogram for Recurrence After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2). First author DOI 10.3390/cancers18071181↗
  4. Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone. Co-author DOI 10.1007/s00262-025-03946-z↗
  5. A case of pancreatic ductal adenocarcinoma growing within the pancreatic duct mimicking an intraductal tubulopapillary neoplasm. Co-author DOI 10.1007/s12328-025-02098-y↗
  6. Robotic posterior radical antegrade modular pancreatosplenectomy for left-sided pancreatic cancer using the ligament of Treitz first approach: A case report an… Co-author DOI 10.1016/j.ijscr.2025.111782↗
  7. Gemcitabine-induced neutrophil extracellular traps via interleukin-8-CXCR1/2 pathway promote chemoresistance in pancreatic cancer. Co-author DOI 10.1038/s41416-025-03192-1↗
  8. Precise stratification of prognosis in pancreatic ductal adenocarcinoma patients based on pre- and postoperative genomic information. Co-author DOI 10.1186/s12935-025-03894-9↗
  9. Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 in Patients with Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers17203287↗
  10. Prognosis Prediction Model After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2). Co-author DOI 10.3390/cancers17223694↗
  11. Robot-Assisted Pancreaticoduodenectomy Using the Anterior Superior Mesenteric Artery-First Approach for Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16305-6↗
  12. Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment. Co-author DOI 10.3390/jcm12020465↗
  13. Feasibility of local therapy for recurrent pancreatic cancer. Co-author DOI 10.1016/j.pan.2022.05.004↗
  14. A Systematic Review of Minimally Invasive Versus Open Radical Antegrade Modular Pancreatosplenectomy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.15523↗
  15. Usefulness of Middle Colic Artery Transposition Technique for Hepatic Arterial Reconstruction in Conversion Surgery for an Initially Unresectable, Locally Adva… Co-author DOI 10.18926/amo/62410↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toshiyoshi Fujiwara · 13 shared papers, 2021–2026 · strength 2.92
  2. Kazuya Yasui · 12 shared papers, 2021–2026 · strength 2.73
  3. Ryuichi Yoshida · 7 shared papers, 2021–2026 · strength 1.34
  4. Takeyoshi Nishiyama · 4 shared papers, 2024–2026 · strength 1.02
  5. Kazuyuki Matsumoto · 4 shared papers, 2025 · strength 1.01
  6. Yuki Fujii · 4 shared papers, 2025–2026 · strength 0.90
  7. Motoyuki Otsuka · 4 shared papers, 2025–2026 · strength 0.90
  8. Yuzo Umeda · 5 shared papers, 2021–2025 · strength 0.88
  9. Yasuo Nagai · 4 shared papers, 2024–2025 · strength 0.87
  10. Shigeru Horiguchi · 3 shared papers, 2025–2026 · strength 0.71
  11. Koichiro Tsutsumi · 2 shared papers, 2025–2026 · strength 0.47
  12. Takehiro Okabayashi MD · 2 shared papers, 2025–2026 · strength 0.46
  13. Kenta Sui · 2 shared papers, 2025–2026 · strength 0.46
  14. Tomohiko Yagi · 2 shared papers, 2025 · strength 0.42
  15. Shohei Nogi · 2 shared papers, 2025 · strength 0.42
  16. Shinji Kuroda · 2 shared papers, 2025 · strength 0.42
  17. Kazuhiro Yoshida · 2 shared papers, 2021–2022 · strength 0.28
  18. Ryosuke Sato · 1 shared paper, 2025 · strength 0.25
  19. Soichiro Ako · 1 shared paper, 2026 · strength 0.22
  20. Daisuke Uchida · 1 shared paper, 2026 · strength 0.22
  21. Tatsuya Kikuchi · 1 shared paper, 2026 · strength 0.22
  22. Hiroyuki Terasawa · 1 shared paper, 2026 · strength 0.22
  23. Hideaki Kinugasa · 1 shared paper, 2026 · strength 0.22
  24. Kanto Suemori · 1 shared paper, 2025 · strength 0.21
  25. Kokichi Miyamoto · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.